The effect of synbiotics on pathophysiology in patients with chronic obstructive pulmonary disease.

The effect of synbiotics on pathophysiology in patients with chronic obstructive pulmonary disease. - The effect of synbiotics on pathophysiology in patients with chronic obstructive pulmonary disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050167

Enrollment

Registered

2023-02-01

Start date

2016-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

GFO(Otsuka Pharmaceutical Factory, Inc.)15g 3times/day + bifidobacteria powder(CLINICO, Co., Ltd.)2g once/day:0ral administration for 6months bifidobacteria powder(CLINICO, Co., Ltd.)2g once/day:0ral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients in stable condition for more than 3 months. patients agreed to participate this study patients without dysphagia

Exclusion criteria

Exclusion criteria: patients with dysphagia patients with severe metabolic disease, cardiovascular disease, hepatic disease, and renal disease

Design outcomes

Primary

Measure	Time frame
circulating inflammatory mediators	—

Secondary

Measure	Time frame
gut microbiota subjective symptoms pulmonary function nutritional status	—

Countries

Japan

Contacts

Public ContactMasanori Yoshikawa

Nara Medical University Division of Nutritional Management

noriy@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026